---
title: "Sermorelin"
canonical_url: https://peptidelibrary.app/library/sermorelin
description: "GHRH(1-29), the shortest fragment of growth hormone-releasing hormone that retains full activity at the pituitary GHRH receptor. It was marketed in the United States as Geref for paediatric growth hormone deficiency and as a diagnostic agent; the brand was discontinued in 2008 for commercial rather than safety reasons, and it remains available through compounding pharmacies. Because it stimulates the pituitary rather than replacing the hormone, it requires an intact somatotroph axis. Prohibited in sport under WADA class S2."
updated: 2026-09-26
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Sermorelin

Sermorelin (also called GRF 1-29 or Geref (discontinued brand)) is a research peptide in the Growth Hormone Secretagogue class. Sermorelin is GRF(1-29), the shortest N-terminal fragment of growth hormone-releasing hormone that retains full biological activity. It binds the GHRH receptor on pituitary somatotrophs, a Gs-coupled receptor whose activation raises cyclic AMP and triggers synthesis and pulsatile release of growth hormone.

GHRH(1-29), the shortest fragment of growth hormone-releasing hormone that retains full activity at the pituitary GHRH receptor. It was marketed in the United States as Geref for paediatric growth hormone deficiency and as a diagnostic agent; the brand was discontinued in 2008 for commercial rather than safety reasons, and it remains available through compounding pharmacies. Because it stimulates the pituitary rather than replacing the hormone, it requires an intact somatotroph axis. Prohibited in sport under WADA class S2.

Also known as: GRF 1-29, Geref (discontinued brand), Sermorelin acetate.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: GHRH(1-29) / discontinued US brand
- Mechanism class: Growth Hormone Secretagogue
- Development stage: Research only
- Regulatory class: Withdrawn or rejected, not approved

## Mechanism

Sermorelin is GRF(1-29), the shortest N-terminal fragment of growth hormone-releasing hormone that retains full biological activity. It binds the GHRH receptor on pituitary somatotrophs, a Gs-coupled receptor whose activation raises cyclic AMP and triggers synthesis and pulsatile release of growth hormone. Because it acts on the pituitary rather than replacing the hormone, it only works where the somatotroph axis is intact, and the resulting GH release remains subject to negative feedback from IGF-1 and somatostatin — a self-limiting property that exogenous growth hormone does not have. Dipeptidyl peptidase-4 cleaves it rapidly, giving a half-life of minutes.

Targets: GHRH receptor.

Origin: Synthetic GHRH(1–29) amide.

## Properties

- Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
- Length: 29
- Molecular formula: C149H246N44O42S
- Molecular weight: 3,357.96 g/mol
- CAS number: 86168-78-7
- Half-life: ~11-12 minutes
- Studied routes: Intravenous, Intranasal, Subcutaneous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 1993

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion. Acta Paediatr Suppl. 1993. 1993. Human study (early or uncontrolled). Population: Human subjects in a dose-response protocol. Growth hormone release and pharmacokinetics [Source](https://pubmed.ncbi.nlm.nih.gov/8329825/)
2. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet. 1987. 1987. Human study (early or uncontrolled). Population: Patients with growth hormone deficiency. Growth response in GH deficiency [Source](https://pubmed.ncbi.nlm.nih.gov/2879138/)
3. NCT01060488 — Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test. Controlled human trial. Population: Adults undergoing growth hormone testing (n=69). Validation of the GHRH-arginine stimulation test [Source](https://clinicaltrials.gov/study/NCT01060488)

### Registered trials

- [NCT01060488](https://clinicaltrials.gov/study/NCT01060488)

## Safety

Side effects: Flushing; Injection pain; Taste changes (IV).

Risks: WADA S2; Brand product withdrawn.

Contraindications: Cancer history.

Human safety basis: Limited human reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

Sermorelin was withdrawn from the market or rejected for approval. It is not an approved product.

- FDA status: Withdrawn / Rejected
- WADA status: Banned in Sport
- Availability: Discontinued

## Frequently asked questions

### What is Sermorelin?

GHRH(1-29), the shortest fragment of growth hormone-releasing hormone that retains full activity at the pituitary GHRH receptor. It was marketed in the United States as Geref for paediatric growth hormone deficiency and as a diagnostic agent; the brand was discontinued in 2008 for commercial rather than safety reasons, and it remains available through compounding pharmacies. Because it stimulates the pituitary rather than replacing the hormone, it requires an intact somatotroph axis. Prohibited in sport under WADA class S2.

### What are the side effects of Sermorelin?

Sermorelin has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include flushing, injection pain and taste changes (IV). Cautions recorded on this profile: cancer history. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.

### How does Sermorelin work?

Sermorelin is GRF(1-29), the shortest N-terminal fragment of growth hormone-releasing hormone that retains full biological activity. It binds the GHRH receptor on pituitary somatotrophs, a Gs-coupled receptor whose activation raises cyclic AMP and triggers synthesis and pulsatile release of growth hormone.

### Is Sermorelin FDA approved?

No. Sermorelin is not currently FDA-approved. Its development or marketing was discontinued, which can happen for commercial reasons as well as safety or efficacy ones. Any material available today is not an approved product.

### What is the half-life of Sermorelin?

Reported half-life for Sermorelin is ~11-12 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Sermorelin?

Sermorelin has the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2, giving a chain of 30 amino acids. Its molecular formula is C149H246N44O42S.

### Is Sermorelin banned in sport?

Sermorelin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [A potentially effective drug for patients with recurrent glioma: sermorelin — Ann Transl Med, 2021](https://pubmed.ncbi.nlm.nih.gov/33842627/)
- [Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026](https://pubmed.ncbi.nlm.nih.gov/41490200/)
- [Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Med, 2026](https://pubmed.ncbi.nlm.nih.gov/41966639/)
- [A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — J Sports Med Phys Fitness, 2026](https://pubmed.ncbi.nlm.nih.gov/41880199/)
- [The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne), 2026](https://pubmed.ncbi.nlm.nih.gov/42395176/)
